The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
In the survey, conducted after the third in the Democratic Party's series of debate, the former vice president draws 31% compared to 25% for the Massachusetts senator. At 14%,...2020 Electionsread more
Stocks rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
The U.S. Air Force's top general says he hasn't received direction to send additional bombers to the Middle East after what is believed to be Iranian attacks on Saudi Arabian...Defenseread more
Facebook has partnered with Ray-Ban maker Luxottica to develop augmented-reality glasses code-named 'Orion', people familiar with the matter told CNBC.Technologyread more
"I believe the path to 'health care for all' is a path following the lead of the Affordable Care Act," House Speaker Nancy Pelosi tells Jim Cramer.Health and Scienceread more
The pet food and product retailer posted net sales of $1.15 billion, topping estimates of $1.13 billion, according to a survey of analysts by Refinitiv.Retailread more
E-cigarette maker Juul Labs Inc.'s sales have been halted on two websites in China, just days after it launched in the world's biggest tobacco market.Biotech and Pharmaceuticalsread more
study (June 8)@ (In June 8 story, corrects first paragraph to clarify that the study compared patients with type 2 diabetes before and after using Abbott's device; In paragraph 4, clarifies that the patients used insulin injections every day over an average of more than 8 years)
June 8 (Reuters) - Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.
The study, which was presented at the American Diabetes Association meeting in San Francisco, assessed the medical records of 363 type 2 diabetics in France, Germany and Austria between three and six months.
Dr. Helene Hanaire of the University Hospital Center of Toulouse, France, one of the study authors, said having ready access to their blood glucose readings helped diabetics become more engaged with controlling their glucose levels.
Patients in the study, whose average age was 63, used multiple insulin injections every day over an average of more than eight years.
An analysis of patient records found that patients who used Abbott's FreeStyle Libre - a device worn on the body that monitors blood sugar continuously through a sensor under the skin - helped patients reduce hemoglobin A1c by nearly 1%.
Hemoglobin A1c levels is a measure of a person's average blood sugar for three months and indicates the risk for developing long-term complications from diabetes.
Patients who used the device for at least three months saw their A1c levels drop to an average of 8%, from the previous level of 8.9%, when they did not use the device. However, this was still above the American Diabetes Association's recommended target of 7%.
Type 2 diabetes is the most common form of diabetes, and many patients can keep their blood sugar within the recommended range with oral medications and do not need insulin. However, those on insulin require regular monitoring of blood sugar levels.
Abbott's FreeStyle Libre, which can be worn for up to 14 days, reduces the need for the traditional fingerstick testing.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by James Emmanuel)